Digest Network Come funziona
Network
/
Società
St
Non verificato

Stoke Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

47 comunicati stampa

Guarda tutti i comunicati
16/01/2026
Salute
Biotecnologia
Scienza
Sanità
Farmaceutica
Mercato azionario
Finanza
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Web e Social Network
Eventi
Industria
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Mercato azionario
Finanza
Scienza
Biotecnologia
Sanità
Salute
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/12/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Fiere
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/12/2025
Scienza
Infanzia
Medicina - Varie
Biotecnologia
Salute
Vetrine/Shopping
Farmaceutica
Eventi
Fiere
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Finanza
Biotecnologia
Farmaceutica
Salute
Sanità
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/11/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0